Published Research and Presentations

ANZUP and our members contribute to national and international publications, presentations and journals – highlighting the clinical research we undertake.

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma

Other

BJU International

22/11/2023

Ciara Conduit , Ian D. Davis, Jeffrey C. Goh, Ganessan Kichenadasse, Howard Gurney, Carole A. Harris David Pook Laurence Krieger, Francis Parnis,, Craig Underhill, Diana Adams, Felicia Roncolato, Anthony Joshua, Tom Ferguson, Prashanth Prithviraj Michelle Morris, Michelle Harrison, Stephen Begbie, Elizabeth Hovey, Mathew George, Elizabeth C. Liow, Emma K. Link, Margaret McJannett, Craig Gedye
Accordion Tab Title 1

Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)

PCR MIB

European Association of Urology

20/09/2023

Andrew Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, Jing Xie, Mark Sidhom, Abhijit Pal, Peter Grimison, Alison Zhang, Siobhan Ng, Colin Tang, Elizabeth Hovey, Colin Chen, George Hruby, Alexander Guminski, Margaret McJannett, Ciara Conduit, Ben Tran, Ian Davis, Dickon Hayne
Accordion Tab Title 1

The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy

Other

BJU International

18/09/2023

Matthew J. Roberts, Ciara Conduit, Ian D. Davis, Rachel M. Effeney, Scott Williams, Jarad M. Martin, Michael S. Hofman, George Hruby, Renu Eapen, Chris Gianacas, Nathan Papa, Richard De Abreu Lourenc Haryana M. Dhillon, Ray Allen, Antoinette Fontela, Baldeep Kaur, Louise Emmett.
Accordion Tab Title 1

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations

Other

16/06/2023

Ciara Conduit, Jeremy Lewin, Andrew Weickhardt, James Lynam, Shirley Wong, Peter Grimison, Shomik Sengupta, Ganes Pranavan, Francis Parnis, Patricia Bastick, David Campbell, Aaron R. Hansen, Matt Leonard, Margaret McJannett, Martin R. Stockler, Peter Gibbs, Guy Toner, Ian D. Davis, Ben Tran, and Anna Kuchel.
Accordion Tab Title 1

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

ENZAMET

The Lancet

03/04/2023

Christopher J Sweeney, Andrew J Martin, Martin R Stockler, Stephen Begbie, Leanna Cheung, Kim N Chi, Simon Chowdhury, Mark Frydenberg, Lisa G Horvath, Anthony M Joshua, Nicola J Lawrence, Gavin Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A North, Francis Parnis, Wendy Parulekar, David W Pook, Martin Neil Reaume, Shahneen K Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G Williams, Diana Winter, Sonia Yip, Alison Y Zhang, Robert R Zielinski, Ian D Davis, for the ENZAMET trial investigators* and Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Accordion Tab Title 1

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

TheraP

16/10/2022

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman, for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Accordion Tab Title 1